180 Life Sciences Corp. (NASDAQ:ATNFW) Sees Significant Decrease in Short Interest

180 Life Sciences Corp. (NASDAQ:ATNFW) was the recipient of a significant decline in short interest in the month of September. As of September 15th, there was short interest totalling 9,500 shares, a decline of 15.9% from the August 31st total of 11,300 shares. Based on an average daily trading volume, of 129,300 shares, the short-interest ratio is presently 0.1 days.

180 Life Sciences Stock Down 11.4 %

180 Life Sciences stock traded down $0.00 during mid-day trading on Monday, reaching $0.01. 578 shares of the company traded hands, compared to its average volume of 102,988. The firm’s 50 day moving average price is $0.01 and its 200 day moving average price is $0.01. 180 Life Sciences has a 52-week low of $0.00 and a 52-week high of $0.03.

180 Life Sciences Company Profile

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor.